We have screened a synthetic peptide combinatorial library composed of 2 ؋ 10 7 -turn-constrained peptides in binding assays on four structurally related receptors, the human opioid receptors , ␦, and and the opioid receptor-like ORL1. Sixty-six individual peptides were synthesized from the primary screening and tested in the four receptor binding assays. Three peptides composed essentially of unnatural amino acids were found to show high affinity for human -opioid receptor. Investigation of their activity in agonist-promoted stimulation of [35 S]guanosine 5-3-O-(thio)triphosphate binding assay revealed that we have identified the first inverse agonist as well as peptidic antagonists for -receptors. To fine-tune the potency and selectivity of these -peptides we replaced their turn-forming template by other turn mimetic molecules. This "turn-scan" process allowed the discovery of compounds with modified selectivity and activity profiles. One peptide displayed comparable affinity and partial agonist activity toward all four receptors. Interestingly, another peptide showed selectivity for the ORL1 receptor and displayed antagonist activity at ORL1 and agonist activity at opioid receptors. In conclusion, we have identified peptides that represent an entirely new class of ligands for opioid and ORL1 receptors and exhibit novel pharmacological activity. This study demonstrates that conformationally constrained peptide combinatorial libraries are a rich source of ligands that are more suitable for the design of nonpeptidal drugs.Opiates exert their pharmacological actions through three receptor types (1, 2), , ␦, and . Their genes have been cloned (see Ref. 3), and the analysis of their amino acid sequence indicated that they belong to the G-protein-coupled receptor family and display a high degree of homology. The cloning of opioid receptors led to the discovery of an additional member for this receptor family referred to as opioid receptor like (ORL1 1 ; see Ref. 4). Although ORL1 shares high sequence similarities with opioid receptors, it does not bind opioid ligands with high affinity.Opiate drugs, the prototype of which is morphine, are largely used in medicine for the treatment of pain, but their administration is associated with severe side effects, including high abuse potential (see Ref. 5). Most nonanalgesic actions of opiates have been associated with the activation of -receptors (6), and the development of ␦-and -compounds both as pharmacological tools and therapeutic agents is an extremely active research field. Unlike opioid receptors, there is only a small number of available ligands for ORL1 including the endogenous heptadecapeptide nociceptin/orphanin FQ (7, 8) hexapeptides, recently identified by Dooley et al. (9) using combinatorial chemistry techniques, and naloxone benzoylhydrazone (10), previously described as a -and -ligand (11). This recently discovered neurotransmitter system is likely to participate in a broad range of physiological and behavioral functions, with possible interactions with th...